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Infl  ammation in Alzheimer’s disease and the 
infl  ammation hypothesis
In addition to amyloid beta (Aβ) and tau protein 
aggregates, the presence of immune-related antigens and 
cells around amyloid plaques in the brains of patients 
with Alzheimer’s disease (AD) has been reported since 
the 1980s [1-3]. Th   ese initial observations brought about 
changes to the previously assumed view of the brain as an 
immunologically isolated organ. In the 1990s, additional 
ﬁ  ndings of activated complement factors, cytokines and a 
wide range of related receptors in the brain of AD 
patients led to the concept of neuro  inﬂ  ammation 
(inﬂ  ammation within the central nervous system (CNS)), 
which suggests that immunological processes in the brain 
are likely to be involved in the pathology of degenerative 
diseases of the CNS. Table  1 lists signs of an altered 
immune response reported in AD patients.
Th   e role of aggregated proteins in the pathology of AD 
had to be re-considered to account for these observations. 
Th  e  inﬂ  ammation hypothesis emerged relatively recently, 
when it became clear that the observations of altered 
immune processes in AD could not be ignored. Neuro-
inﬂ   ammation is still considered to be a downstream 
consequence in the amyloid hypothesis, with Aβ amyloid 
within the CNS bringing about activation of microglia, 
initiating a pro-inﬂ  ammatory cascade that results in the 
release of potentially neurotoxic substances, including 
cytokines, chemokines, reactive oxygen and nitrogen 
species, and various proteolytic enzymes, leading to 
degenera  tive changes in neurons [4-7]. It has also been 
suggested that activation of microglia may lead to phos-
phorylation of tau and formation of neuroﬁ  brillary 
tangles (NFTs) [8-10]. However, the exact role of inﬂ  am-
mation in the pathology of AD and its mechanisms in 
terms of the cells involved - microglia, astrocytes and 
T lymphocytes - are still debated.
Th  e inﬂ   ammation hypothesis is also supported by 
epidemiological retrospective observations that patients 
with rheumatoid disease who are on long-term anti-
inﬂ   ammatory therapy have a lower prevalence of AD 
[11-15]. Other largely observational studies have also 
supported the concept that anti-inﬂ  ammatory approaches 
may be protective against the development of AD [16,17]. 
Furthermore, transgenic animal studies and human trials 
have demonstrated that treatment with nitric oxide-
releasing non-steroidal anti-inﬂ  ammatory drugs (NSAIDs) 
can reduce and/or prevent the AD pathology (reviewed 
by McGeer and McGeer [18]). It has also been shown 
that a certain drug with anti-inﬂ  ammatory  properties 
(CNI-1493) suppresses amyloid pathology and improves 
memory performance in transgenic mice [19]. Despite 
these ﬁ  ndings, however, several prospective anti-inﬂ  am-
matory strategies against disease progression in subjects 
with established AD have failed to show convincingly 
positive results (see the ‘Current treatment strategies 
based on the inﬂ  ammation hypothesis’ section below). 
Although these eﬀ  ects did not reach signiﬁ  cant levels in 
large human cohorts [20], interest in the inﬂ  ammatory 
processes of AD pathology has persisted [21,22]. One 
particularly interesting aspect of these studies was that 
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of anti-inﬂ  ammatory drugs was not necessarily attributed 
to down-regulation of inﬂ  ammatory processes. Instead, 
activation of microglia via a route that enhances its 
phago  cytic activity against Aβ was suggested [23].
Th  e inﬂ   ammation hypothesis also suggests another 
approach to sporadic AD and associated risk factors for 
investigation - polymorphism of genes related to induc  tion 
and regulation of inﬂ  ammatory processes. Initial studies 
suggested a role for speciﬁ  c cytokine polymorphisms - 
for example, in the genes encoding IL-1 and TNFα 
[24,25] - with evidence that IL-1 polymorphism may be 
associated with diﬀ  ering degrees of microglial activation 
in AD [26]. However, a meta-analysis of genetic inﬂ  u-
ences in AD has not supported the initial ﬁ  ndings of 
cytokine gene variation as a risk factor for AD, but has 
instead emphasised the over-riding importance of the 
APOE gene polymorphism as the major genetic risk 
factor [27]. Although many mechanisms for the role of 
apolipoprotein E (APOE) in AD pathogenesis have been 
suggested [28], the key mechanism remains unclear. Of 
particular interest to the inﬂ  ammation hypothesis is the 
ﬁ   nding that APOE ε4 carriers with AD have more 
marked microglial activation [29].
Research into the role of inﬂ  ammation in AD is driven 
by questions similar to those posed for Aβ and abnormal 
tau accumulation. Can neuroinﬂ  ammation be the cause 
of AD? Are the inﬂ  ammatory processes in AD contribut-
ing to the disease pathology? Alternatively, are they 
merely the consequence of the disease, initiated and 
driven by the neurodegeneration? Does inﬂ  ammation act 
as a harmless bystander in the disease course? Can the 
immune processes of the brain be harnessed to ﬁ  ght 
against the disease pathology?
Inﬂ   ammation as the sole cause of AD is usually 
considered as unlikely on the basis that peripheral 
systemic disorders rarely start with inﬂ  ammation - there 
is an initial challenge that is required to stimulate an 
immune (or inﬂ   ammatory) response [30]. However, it 
should be noted that being a response to an insult rather 
than an insult itself, inﬂ   ammation plays an important 
role in the reaction of an organism to this insult, with 
potentially damaging and sometimes fatal consequences 
(for example, in allergy). Autoimmune diseases can aﬀ  ect 
the CNS (for example, paraneoplastic syndromes, 
multiple sclerosis) but there is little evidence to suggest 
that AD falls into this category.
With respect to whether inﬂ  ammatory processes in AD 
contribute to the disease pathology, a lot of evidence has 
accumulated suggesting that inﬂ  ammation can contribute 
to the AD process and exacerbate the course of the 
disease. It is still unclear exactly how inﬂ  ammation acts 
on the diseased brain, as most of the observations about 
the mechanisms of its action are based on animal models. 
However, the supportive evidence for inﬂ  ammation being 
a contributor to the disease process is as follows. First, 
the cognitive state of AD patients who also have short-
term peripheral infection show signs of sudden decline in 
cognitive state, and rarely return to the previous level 
even after recovery from the infection [31]. Second, 
community-based studies suggest that plasma levels of 
inﬂ  ammatory proteins, including cytokines, are increased 
before clinical onset of dementia, including AD [32], 
which may be exacerbated by the presence of athero-
sclerosis [33]. Th  ird, observed signs of inﬂ  ammation in 
the brain of AD patients are comparable to those seen in 
peripheral inﬂ  ammatory reactions and are likely to have a 
strong cytotoxic eﬀ  ect on neurons [5,30]. Fourth, signs of 
inﬂ  ammation are particularly localised in the brain areas 
aﬀ  ected by AD pathology and co-localise with plaques 
and tau deposits [1,2,34-40]. Fifth, high pathology controls 
(individuals who have Aβ and tau aggregates at levels 
similar to AD patients, but do not develop dementia) 
show lower signs of inﬂ   ammation [41]. Sixth, Mini 
Table 1. Signs of altered immune response in Alzheimer’s   disease patients and relevant references
Signs of altered immune response  References
Presence of HLA-DR or LFA-1 (leucocyte function-associated antigen) positive reactive microglia around senile plaques  [1,2,35,37,40]
Increased hippocampal gene expression of MHC II in AD compared to high-pathology controls  [95]
Elevated brain levels of IL-1β and S-100  [3]
Presence of activated elements of classical complement pathway (C1q, C3d, C4d) within dystrophic neurites, NFTs and/or Aβ plaques [34,36,96]
Up-regulated mRNA levels of complement elements C1q and C9 in AD brain  [97]
Strong IL-6 immunoreactivity around plaques and large cortical neurons  [38]
Low levels of TNFα in brain areas with AD pathology  [39]
Increased levels of TNFα in sera of severe stage AD patients  [98]
Increased levels of intracellular neuronal IL10, IFNγ and IL12 in AD patients compared to age-matched controls  [99]
Correlations between Mini Mental State Examination scores and in vivo imaging marker [11C](R)PK11195-PET of activated microglia in AD patients  [42]
Aβ, amyloid beta; AD, Alzheimer’s disease; IFN, interferon; NFT, neurofi  brillary tangle.
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with the level of cortical microglial activation as observed 
from in vivo imaging studies [42].
From these observations, inﬂ  ammation could contri-
bute to the course of AD in two ways. Firstly, as an initial 
innate immune response to the changes in the AD brain. 
In the periphery, the innate immune system generates a 
non-speciﬁ  c response to an invading pathogen or a cell 
stress stimulus as a general ﬁ  rst-line defence mechanism. 
Inﬂ  ammation is part of this response, involving signalling 
via cytokines and via activation of the complement 
system to recruit the immune cells to the site of stress. In 
the periphery, this response is also often referred to as an 
acute, strong, but short-lived immune reaction. In the 
context of AD, association of microglia - the immune 
system cells of the CNS - with plaques and NFTs has 
been observed, suggesting involvement of innate 
immunity in the reaction to the AD-related stimuli. 
Observations of acute-phase inﬂ  ammatory proteins along-
side cytokines and chemokines associated with plaques 
and tangles in AD have been reported, suggestive of 
multiple ways of interaction between these inﬂ  ammatory 
mediators [5]. Th  e presence of elements of the comple-
ment system and membrane attack complex C5b-9, in 
particular, has been reported to correlate highly with the 
level of synaptic loss [41]. Th  is engagement of the 
complement system has not been observed in the brains 
of high pathology controls, contributing to evidence of 
the involvement of acute mediators in AD. Th  e C5b-9 
complex is known to be very potent at killing or 
damaging neurons through signalling for production of 
various cytokines and other complement elements [30]. 
However, most studies refer to inﬂ  ammation in AD as 
weak and non-speciﬁ  c. Th   is is explained on the basis of 
the presence of multiple mechanisms that regulate 
inﬂ  am  matory reactions within the brain and minimise 
them [43]. Nevertheless, long exposure to ongoing 
inﬂ   am  mation signalling, even at low levels, can bring 
about gradual neurodegeneration that might be more 
diﬃ     cult to stop or reverse than acute inﬂ  ammatory 
episodes observed in peripheral disorders [30].
Secondly, the low-level ongoing inﬂ   ammation in AD 
contributing to the course of the disease can be a sign of 
impaired adaptive immune responses leading to chronic 
inﬂ   ammation. In the periphery, an innate immune 
response is followed by a switch to an adaptive response 
with generation of antibodies and overall down-regu  lation 
of acute pro-inﬂ  ammatory signalling. Th   e func  tions of the 
adaptive immune response include induction of more 
speciﬁ   c and stronger defence mechanisms against 
abnormal stimuli, and engagement of memory T cells that 
can recognise and eliminate the same stimulus more 
quickly and eﬃ   ciently if it is encountered again in the 
future. Th   e important feature of this type of response is to 
be able to recognise ‘non-self’ antigens and distinguish 
them from ‘self’. In the context of AD pathology, Aβ 
plaques and NFTs persist, accompanied by ongoing 
inﬂ  ammation over a long period of time, during which the 
disease progresses. It is suggested, therefore, that after 
induction of the initial immune response, when plaques 
and tangles are recognised as invading stimuli, transition 
to the adaptive immune response and the mechanism of 
recognition of plaques and tangles as persisting stress 
stimuli is impaired. With respect to microglia in AD, this 
eﬀ  ect is reﬂ  ected by their inability to transit from an initial 
classic state (also referred to as pro-inﬂ  ammatory or Th  1-
induced) to an alternative (anti-inﬂ   ammatory or Th  2-
induced) immune response. Impaired activation of 
microglial Toll-like receptors in AD brain has also been 
suggested [44-46]. Th   e result is that phagocytic activity as 
well as the neuroprotective function of microglia are 
impaired [47].
Th  e type of inﬂ  ammation in the AD brain is not well 
deﬁ   ned and is often blamed on ‘dysfunctional’ or 
‘malactivated’ microglia [48]. Th  e exact proﬁ   le of these 
microglia has not yet been well characterised [4], but the 
description is often based on observation of a single 
marker or a dystrophic and apoptotic appearance of the 
cells [48-50].
Some studies report the presence of auto-antibodies 
against Aβ in older people [51], and possible involvement 
of T and B cells in the AD process [52,53]. However, 
conclusive positive evidence for direct involvement of 
antibody-mediated response in AD has not yet been 
presented [30].
One could also suggest that inﬂ  ammation observed in 
the brains of AD patients is merely a consequence of the 
disease, pointing to an inability of microglia to clear ever-
growing neuronal debris due to extensive neuro  degenera-
tion and synaptic loss. Impaired recruitment of mono  cytes 
from the periphery to the site of the disease in AD brain 
has been suggested in this respect and demon  strated using 
animal models [54-56].
Th   e phagocytic proﬁ  le of microglia that is often referred 
to in AD brain is generally non-aggressive, aiming at 
clearing the damage/debris with minimal further damage 
to the surrounding tissue, leading to the question: can 
inﬂ  ammatory activity in AD brain have a neutral or even 
beneﬁ  cial role? However, another per  spective comes from 
studies using a model of neuro  degeneration - the ME7 
mouse model of prion disease [57]. Th   ese studies suggest 
that microglia in the context of a neurodegenerative 
disease, although generally in an anti-inﬂ  ammatory state, 
are ‘primed’ to switch quickly into an aggressive proﬁ  le 
should the opportunity arise. Such an opportunity may be 
a peripheral infection, as demonstrated in this model [58].
Mixed and often contradictory ﬁ  ndings with respect to 
inﬂ   ammation in AD indicate the complexity and 
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apparent that inﬂ   ammation in the CNS, as in the 
periphery, is a mixture of both destructive and rebuilding 
processes. Th   e balance between these processes 
determines the overall integrity of the tissue or the whole 
organism [59]. Th  erefore, inﬂ   ammation should not be 
viewed as wholly detrimental or beneﬁ   cial in AD. 
Understanding of the whole spectrum of the immune 
processes involved is necessary to ﬁ   nd an optimal 
solution for the prevention or treatment of the disease.
Th  e possibility of harnessing immune processes to 
direct the system towards clearance of the disease 
features has become an actively researched topic of AD. 
Much AD research is now aimed at modulation of the 
immune system to direct it away from microglial activa-
tion that is pro-inﬂ  ammatory (or malactivated) towards a 
more controlled productive and phagocytic antibody-
mediated immune response [60].
In summary, the pathological changes associated with 
AD as described above should not be considered in 
isolation. It is more likely that their cumulative action 
results in disruption of the normal work of the CNS 
through damage to neurotransmitter systems, neuronal 
dysfunction and death.
Current treatment strategies based on the 
infl  ammation hypothesis
Two main treatment approaches addressing inﬂ  amma  tory 
processes in AD, but from diﬀ   erent perspectives, have 
been investigated so far. Th  e use of anti-inﬂ  ammatory 
drugs aims to down-regulate the inﬂ   am ma tion  in  AD 
brain for a potential beneﬁ  cial  eﬀ   ect, whereas the 
immunotherapy approach aims to harness the immune 
system and direct it against the pathological features of the 
disease, mainly Aβ deposition. Th  e advances in, and 
limitations of, both approaches are discussed below.
Anti-infl  ammatory drugs
As mentioned above, retrospective studies of patients 
who were on NSAIDs long-term showed that these 
patients had a lower prevalence of AD. Th  ese obser  va-
tions have generated interest in anti-inﬂ  ammatory 
strategies for AD. Th   e approach was tried in APPSW and 
APP-PS1 transgenic mouse models of AD using nitric 
oxide-releasing NSAIDs [23,61]. Both studies showed 
that treatment with these drugs reduces and/or prevents 
AD pathology in the animals. Th  e involvement of 
microglia was suggested, but the results were contra-
dictory, reporting decreased microglial activation in the 
APPSW model [61] but surprisingly raised levels of 
activated microglia in the APP-PS1 model [23]. An eﬀ  ect 
of NSAIDs in decreasing secretion of Aβ was observed in 
cultured cells [62]. However, the mechanism of action of 
the NSAIDs is not understood. Epidemiological studies 
show various degrees (up to 50%) of beneﬁ  cial eﬀ  ect from 
the use of NSAIDs on the onset of the disease and 
dementia, with increased duration of drug use having a 
positive eﬀ   ect by reducing the relative risk of AD 
[16,17,20]. However, the results from randomized 
controlled clinical trials did not show any beneﬁ  cial eﬀ  ect 
(reviewed by McGeer and McGeer [18]). Conventional 
NSAIDs can also cause undesirable side-eﬀ  ects  (for 
example, gastrointestinal ulceration) [20].
Immunisation
Driven by the amyloid hypothesis and by observations of 
microglia surrounding plaques in AD, but being unable 
to clear the plaques in animal models of AD and in 
human post-mortem observations, the immunisation 
approach has emerged. Th   e idea of modifying the immune 
system and directing it towards eﬀ   ective clearance of 
plaques has generated a lot of interest.
Animal studies
In animal models, immunotherapy has been reported to 
prevent the formation of and to clear existing Aβ 
deposits, and to remove dystrophic neurites [63-75]. Th  e 
ﬁ   rst reported immunisation study used PDAPP trans-
genic mice and synthetic human Aβ42 peptide as the 
antigen [63]. Th  e animals developed a high antibody 
response (titre 1:10,000). Complete prevention of 
amyloid and neuritic pathology was achieved in mice 
immunised at 6  weeks of age, and extensive plaque 
clearance was achieved in older mice immunised at 
11 months of age. Older immunised animals also showed 
Aβ-containing cells with an activated microglial 
phenotype, suggestive of Fc receptor-mediated clearance 
of Aβ42. Signiﬁ  cant reduction in neuritic pathology as 
well as reactive astrocytosis were also observed in the 
older immunised group when compared to untreated 
controls.
Th   is work was followed by similar studies using Tg2576 
and TgCRND8 APP transgenic mice. Active immuni  za-
tion in these models showed various levels of plaque 
clearance (up to 50%), signiﬁ  cant behavioural improve-
ments in older animals, and prevention of cognitive 
deﬁ  cit in a younger group [64,66].
Administration of antibodies against Aβ (m266, 3D6, 
10D5, PabAβ1-42) directly into the brain or via the 
periphery (passive immunisation) in PDAPP transgenic 
mice also showed ﬁ  ndings similar to active immunisation 
with regard to reduction of AD-like pathology through 
clearance of Aβ plaques and improved memory and 
learning performance [65,67,69,70]. In one study, 
however, memory deﬁ   cits were reversed even without 
alteration to Aβ burden [70].
Th  ese studies posed questions about possible mecha-
nisms of plaque clearance. Amyloid-antibody complex 
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one possible mechanism [65]. A non-Fc-mediated 
mecha  nism of direct plaque destruction with F(ab΄)2 
antibody fragments that lack the Fc component was also 
proposed [69]. However, the role of Fc receptor-mediated 
phagocytosis in plaque clearance after immunotherapy 
was questioned when Aβ clearance was observed in 
actively immunised phagocytosis-deﬁ  cient (FCR-/-) APP 
mice at levels similar to FcR non-deﬁ  cient APP mice [71]. 
Equally, the ability of F(ab΄)2 fragments to activate 
microglia and remove amyloid ﬁ   brils was questioned 
when another study showed that these fragments fail to 
activate microglia and are less eﬀ   ective than IgG 
antibodies at clearing plaques [76]. A two-step mecha-
nism of plaque removal using anti-Aβ antibodies was 
proposed: an initial rapid decrease in Aβ deposition 
24  hours after antibody administration, followed by 
microglia-dependent removal 3 days after antibody injec-
tion [72]. A ‘sink’ mechanism was also proposed in which 
monoclonal antibody to Aβ may attract Aβ across the 
blood-brain barrier from the brain into the periphery [67].
Although these studies showed that immunisation with 
Aβ was successful in animals, the models used, however, 
did not reﬂ  ect the full pathology of AD (that is, they 
lacked NFTs or substantial neurodegeneration despite 
Aβ deposition). It was not clear from these studies if 
generation of anti-Aβ antibodies and removal of amyloid 
would show improvement of cognition in humans. Safety 
issues were also highlighted with respect to the 
acceptable and eﬀ  ective levels of antibodies that can be 
used in animals versus humans, the preference of the 
active over passive immunisation approach, and the exact 
mechanism of action of the vaccine [77]. Th  e antibody 
levels in animals had to be quite high to reach the desired 
eﬀ  ect of Aβ removal. Th  e concern was whether suﬃ   -
ciently high levels of anti-Aβ antibody can be safely 
produced in humans. A detailed mechanism of action 
initiated by the immunotherapy was also not established.
Despite these concerns and unanswered questions, the 
immunisation approach progressed to human clinical 
trials (see the ‘Human clinical trials’ section below). 
Following the halting of the active immunisation phase 
IIa trial (conducted by Elan Pharmaceuticals) due to an 
inﬂ  ammatory side-eﬀ  ect in a subset of patients, more 
recent animal immunisation studies have been focusing 
on induction of a controlled immune response to AD 
pathology that avoids strong pro-inﬂ  ammatory reaction. 
A necessity for a model that would reﬂ   ect the full 
pathology of the disease led to the generation of the triple 
transgenic mouse model (3×Tg-AD), which shows Aβ 
deposition as well as tangle formation, synaptic degenera-
tion and behavioural impairments [78,79]. Recent immu-
nisation studies using this model showed that intra-
hippocampal administration of Aβ antibodies clears or 
prevents plaque formation as well as clears early 
phosphorylated tau [80]. Th   e same group further investi-
gated the eﬀ  ect of active and passive Aβ immunisation 
and demonstrated the importance of clearing both 
soluble Aβ and soluble tau for the improvement of 
cognitive performance [81]. Th   e latest active immunisa-
tion animal study in the Tg2576 model aimed to show 
that using non-toxic, non-ﬁ   brillogenic forms of Aβ 
together with an adjuvant that promotes a humoral, 
rather than a cell-mediated, response is eﬀ  ective  in 
removal of AD pathology without adverse inﬂ  ammatory 
eﬀ   ects and microhaemorrhages [75]. Th  is study also 
conﬁ   rmed that immunisation is more eﬀ  ective at early 
stages of the disease. Th  e same group tested active 
immunisation with diﬀ  erent Aβ species in young lemur 
primates in order to evaluate the antibody response and 
choose the most eﬃ   cient peptide and adjuvant for further 
studies in old lemurs [82]. Tau-speciﬁ  c immuni  sation in 
various models of tauopathies is also underway [83].
Human clinical trials
Clinical trials testing the active immunisation approach 
against Aβ42 were set up by Elan Pharmaceuticals. Th  e 
ﬁ  rst multicentre randomised multiple-dose double-blind 
human trial (phase I) was designed to assess the anti-
genicity, safety and tolerability of the developed treat-
ment, and was performed between April 2000 and June 
2002. Eighty mild to moderate stage AD patients 85 years 
old or less were recruited in the south of the United 
Kingdom. Of the recruited patients, 64 received multiple 
doses of 50 or 225 μg of Aβ42 peptide in combination 
with the QS21 adjuvant (AN-1792), and 16 received 
adjuvant alone (placebo). Four injections were admini-
stered at weeks 0, 4, 12, and 24, with permission to 
administer additional injections at weeks 36, 48, 60 and 
72. Patients were assessed every 2 to 3 weeks. At the end 
of the study, it was reported that the treatment was well 
tolerated. Approximately 25 to 50% of the patients who 
received the active treatment developed a positive 
immune response to AN-1792 [84].
In June 2001, a further study was initiated with a larger 
patient sample (phase IIa); 375 patients were recruited in 
Europe and the USA, of which 300 were to receive 
multiple doses of 225 μg AN-1792. Th   is trial was halted 
after several months as 18 patients developed aseptic 
meningoencephalitis [85].
Th  e clinical report from the phase IIa study showed 
that most of the patients who developed this inﬂ  am-
matory side-eﬀ  ect were considered as antibody responders 
with varied levels of IgG and measurable IgM levels in 
serum, although these levels had no obvious correlation 
with the incidence or severity of meningoencephalitis 
[85]. Th  e event was predominantly singular, but four 
patients had moderate or severe relapses. Most of the 
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confusion, headache, or lethargy. A high white blood cell 
count was detected in the cerebrospinal ﬂ  uid (15 to 130 
cells per μl) with no signs of viral or bacterial infection. 
Twelve patients recovered to baseline status, and six 
patients continued to decline cognitively after the event.
Whilst a report on the 1-year clinical follow-up of a 
subset of 30 immunized AD patients from the phase IIa 
study suggested evidence of a reduced cognitive decline 
in patients who generated antibodies against β-amyloid 
[86], a 1-year follow-up of all patients showed no signiﬁ  -
cant ﬁ   ndings on clinical outcomes [87]. Furthermore, 
long-term (5 year) clinical and neuropathological follow-up 
of patients from the phase I trial showed that despite an 
antibody response, no overall positive eﬀ  ect on cognition 
was observed - the decline was similar to control patients 
[88]. In the whole cohort, there was no evidence of 
improved survival or of an improvement in the time to 
severe dementia.
Neuropathological reports on patients from the phase I 
and IIa studies all reported similar ﬁ  ndings [88-93]. A 
signiﬁ  cant reduction in Aβ pathology was evident, as well 
as resolution of some tau features (dystrophic neurites). 
Th  e remaining Aβ plaques showed dense core morph-
ology and patchy distribution in the aﬀ  ected brain areas. 
No eﬀ  ect on NFTs was found. Most cases also reported 
signs of Aβ particles within microglia, suggesting 
immunisation-induced Aβ phagocytosis.
A comparison between neuropathological and clinical 
data in eight of the immunised patients from the phase I 
study showed that the degree of plaque removal 
correlated with the mean antibody response attained 
during the treatment study period [88]. However, these 
patients had severe end stage dementia before death, 
including those with virtually complete plaque removal, 
with the exception of one patient, who had died very 
shortly after their ﬁ  rst immunisation dose (due to a cause 
unrelated to the immunisation treatment). Th  e conclu-
sion was that although immunisation with Aβ resulted in 
clearance of amyloid plaques in patients with AD, this 
clearance did not prevent progressive neurodegeneration.
Th  e initial Aβ immunisation clinical trials therefore 
had mixed results and the information obtained has been 
inﬂ  uencing the development of subsequent trials. Several 
clinical trials involving active and passive immunisation 
in AD are currently underway [94]. Th  ese include early 
phase active immunisation studies aimed at the carboxyl 
terminus of Aβ (amino acids 1 to 6; Novartis), passive 
immunisation using antibodies against the amino 
terminus (amino acids 33 to 40; Pﬁ  zer) and the use of 
intravenous immunoglobulin (Baxter Bioscience). Later 
phase passive immunisation studies include the use of 
antibodies to the mid-region of Aβ (amino acids 13 to 28; 
Lilly) and to the amino terminus (Bapineuzumab; amino 
acids 1 to 5; Elan). Th  e latter has now entered a large 
phase III clinical trial with initial ﬁ  ndings in an earlier 
study suggesting a beneﬁ  cial  eﬀ   ect for subjects not 
carrying the APOE ε4 allele.
Conclusion
Research into the inﬂ   ammation in AD so far has 
demonstrated the complexity of the mechanisms involved, 
which interact with each other in multiple ways. Th  is  web 
of interactions makes it diﬃ   cult to isolate any particular 
inﬂ  ammatory process, element or cell and pinpoint its 
individual role in the progress of the disease. Immuni-
sation as one of the AD treatment approaches has led to 
an increased interest in the immune processes associated 
with this disease and highlighted their role in AD 
pathogenesis. Th   e ability to modulate the immune system 
by active immunisation to generate anti-Aβ antibodies 
and stimulate clearance of amyloid plaques underlined 
the potentially beneﬁ  cial eﬀ  ect that the immune system 
can have on the pathology of the disease. Th  e inﬂ  am-
matory response side-eﬀ  ect developed by some immunised 
patients pointed to the complexity of the immune 
processes acting in the brain and their potential for 
harmful eﬀ  ects. Microglia, as the main representative of 
the immune system in the CNS, play an important role in 
both of these eﬀ  ects. Th  eir mechanism of action in AD 
pathogenesis and in the context of Aβ immunisation is 
still not clear. Th   is review aimed to highlight the necessity 
of approaching current and future research into AD from 
multiple directions, and the importance of addressing 
neuro-immune interactions involved in the whole course 
of the disease when devising potential treatment 
strategies.
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